GA
VRTX icon

GraniteShares Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

GraniteShares Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$919K Sell
2,058
-506
-20% -$236K 0.66% 53
2025
Q4 		$1.16M Buy
2,564
+42
+2% +$18.1K 0.71% 55
2025
Q3 		$988K Buy
2,522
+236
+10% +$98.6K 0.57% 58
2025
Q2 		$1.02M Sell
2,286
-28
-1% -$12.9K 0.63% 57
2025
Q1 		$1.12M Sell
2,314
-150
-6% -$69.9K 0.72% 54
2024
Q4 		$992K Sell
2,464
-219
-8% -$102K 0.63% 60
2024
Q3 		$1.25M Sell
2,683
-135
-5% -$64.8K 0.84% 53
2024
Q2 		$1.32M Buy
2,818
+90
+3% +$39.1K 0.44% 54
2024
Q1 		$1.14M Buy
2,728
+16
+0.6% +$6.76K 0.6% 57
2023
Q4 		$1.1M Sell
2,712
-446
-14% -$165K 0.99% 54
2023
Q3 		$1.1M Buy
3,158
+2,406
+320% +$841K 1.02% 48
2023
Q2 		$265K Sell
752
-12
-2% -$4.04K 0.24% 90
2023
Q1 		$241K Sell
764
-12
-2% -$3.6K 0.21% 107
2022
Q4 		$224K Sell
776
-151
-16% -$46K 0.19% 129
2022
Q3 		$268K Sell
927
-106
-10% -$30.5K 0.22% 115
2022
Q2 		$291K Sell
1,033
-102
-9% -$27.3K 0.21% 113
2022
Q1 		$296K Sell
1,135
-100
-8% -$23.7K 0.16% 136
2021
Q4 		$271K Buy
+1,235
New +$240K 0.13% 148

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

GraniteShares Advisors's VRTX Position: Q1 2026 in Review

GraniteShares Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 20% in Q1 2026, selling an estimated $236K and leaving 2,058 shares worth $919K. The position accounts for 0.66% of the portfolio, ranked #53.

GraniteShares Advisors first reported a position in VRTX in Q4 2021 and has held it in 18 quarters since. The position peaked at $1.32M in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • GraniteShares Advisors held 2,058 shares of Vertex Pharmaceuticals worth $919K as of Q1 2026.
  • GraniteShares Advisors sold 506 Vertex Pharmaceuticals shares in Q1 2026, an estimated $236K.
  • Vertex Pharmaceuticals made up 0.66% of GraniteShares Advisors's portfolio in Q1 2026, its #53 holding.
  • GraniteShares Advisors first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
  • GraniteShares Advisors's Vertex Pharmaceuticals position peaked at $1.32M in Q2 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on GraniteShares Advisors's 13F filing for Q1 2026, filed 23 Apr 2026.